{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:50:38Z","timestamp":1763560238054,"version":"3.45.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12328-025-02218-8","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:34:12Z","timestamp":1757356452000},"page":"1114-1117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Crohn\u2019s disease exacerbated by ghost pills of upadacitinib"],"prefix":"10.1007","volume":"18","author":[{"given":"Chihiro","family":"Yunomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kojimahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3716-3386","authenticated-orcid":false,"given":"Keiichi","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimari","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Goda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Irisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"issue":"9853","key":"2218_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380(9853):1590\u2013605.","journal-title":"Lancet"},{"issue":"24","key":"2218_CR2","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.3748\/wjg.v27.i24.3440","volume":"27","author":"A Aksan","year":"2021","unstructured":"Aksan A, Farrag K, Blumenstein I, et al. Chronic intestinal failure and short bowel syndrome in Crohn\u2019s disease. World J Gastroenterol. 2021;27(24):3440\u201365.","journal-title":"World J Gastroenterol"},{"issue":"21","key":"2218_CR3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388(21):1966\u201380.","journal-title":"N Engl J Med"},{"issue":"4","key":"2218_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.2174\/157488412803305786","volume":"7","author":"SE Leucuta","year":"2012","unstructured":"Leucuta SE. Drug delivery systems with modified release for systemic and biophase bioavailability. Curr Clin Pharmacol. 2012;7(4):282\u2013317.","journal-title":"Curr Clin Pharmacol"},{"issue":"7","key":"2218_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jat\/26.7.448","volume":"26","author":"DT Anderson","year":"2002","unstructured":"Anderson DT, Fritz KL, Muto JJ. Oxycontin: The concept of a \u201cghost pill\u201d and the postmortem tissue distribution of oxycodone in 36 cases. J Anal Toxicol. 2002;26(7):448\u201359.","journal-title":"J Anal Toxicol"},{"issue":"6","key":"2218_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/jgf2.134","volume":"18","author":"M Iwamuro","year":"2017","unstructured":"Iwamuro M, Morishita Y, Urata H, et al. Ghost tablet in feces. J Gen Fam Med. 2017;18(6):483\u20134.","journal-title":"J Gen Fam Med"},{"issue":"4","key":"2218_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/flgastro-2024-102668","volume":"15","author":"AT Elford","year":"2024","unstructured":"Elford AT, Bishara M, Plevris N, et al. Real-world effectiveness of upadacitinib in Crohn\u2019s disease: a UK multicentre retrospective cohort study. Frontline Gastroenterol. 2024;15(4):297\u2013304.","journal-title":"Frontline Gastroenterol"},{"issue":"6","key":"2218_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s11605-009-1151-9","volume":"14","author":"N Ward","year":"2010","unstructured":"Ward N. The impact of intestinal failure on oral drug absorption: a review. J Gastrointest Surg. 2010;14(6):1045\u201351.","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"2218_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0305047","volume":"19","author":"V Berger","year":"2024","unstructured":"Berger V, Reeh M, Scherer M, et al. Enhancing drug therapy in ostomy patients: best practice recommendations for medication management. PLoS ONE. 2024;19(6):e0305047.","journal-title":"PLoS ONE"},{"issue":"4","key":"2218_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1053\/gast.2002.32362","volume":"122","author":"DA Schwartz","year":"2002","unstructured":"Schwartz DA, Loftus EV Jr., Tremaine WJ, et al. The natural history of fistulizing Crohn\u2019s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):875\u201380.","journal-title":"Gastroenterology"},{"issue":"5","key":"2218_CR11","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, International Organization for the Study of IBD, et al. Stride-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"issue":"2","key":"2218_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jcph.1513","volume":"60","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, Beck D, Camp HS, et al. Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol. 2020;60(2):188\u201397. https:\/\/doi.org\/10.1002\/jcph.1513.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2218_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"2218_CR14","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","volume":"21","author":"S Friedberg","year":"2023","unstructured":"Friedberg S, Choi D, Hunold T, et al. Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience. Clin Gastroenterol Hepatol. 2023;21(7):1913-23.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2218_CR15","unstructured":"Garc\u00eda MJ, Brenes Y, Vicu\u00f1a M, et al. Persistence, Effectiveness, and Safety of Upadacitinib in Crohn\u2019s disease and Ulcerative Colitis in Real Life: Results from a Spanish Nationwide Study (Ureal Study): Upadacitinib for IBD. Am J Gastroenterol. 2024 Nov 26. [Online ahead of print.]"},{"issue":"2","key":"2218_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1208\/s12249-016-0521-3","volume":"18","author":"M Fischer","year":"2017","unstructured":"Fischer M, Siva S, Wo JM, Fadda HM. Assessment of small intestinal transit times in ulcerative colitis and Crohn\u2019s disease patients with different disease activity using video capsule endoscopy. AAPS PharmSciTech. 2017;18(2):404\u20139.","journal-title":"AAPS PharmSciTech"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-025-02218-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:46:36Z","timestamp":1763559996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-025-02218-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2218"],"URL":"https:\/\/doi.org\/10.1007\/s12328-025-02218-8","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"14 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}]}}